Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Sexual Health Reports
Erschienen in: Current Sexual Health Reports 2/2024

02.04.2024

Inflammation as a Potential Mechanism Contributing to Sexual Functioning Following Initiation of Gender-Affirming Hormone Therapy

verfasst von: Molly K. Irvin, Dannielle Schutz, Tierney K. Lorenz

Erschienen in: Current Sexual Health Reports | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Many transgender and gender non-conforming (TGNC) people seek gender-affirming hormone therapy (GAHT). While GAHT is generally safe and increases well-being, it is essential to accurately understand potential unintended effects and risk factors to better inform and manage treatment. This narrative review covers recent literature documenting changes in sexual function following the initiation of GAHT and explores inflammation as a potential mediator of these changes.

Recent Findings

Generally, the initiation of GAHT is correlated with increased sexual desire in transgender men and decreased sexual desire in transgender women, with time-limited effects that return to levels approaching baseline after about a year; there are also changes in inflammation markers that parallel this timeline. Findings on other aspects of sexual function (e.g., orgasm, pain, and sexual quality of life) are more limited. As there is evidence from cisgender populations that inflammation acts as a mechanism by which hormones influence sexual function, we propose applying this model to TGNC people taking GAHT.

Summary

Sexual function may change in TGNC patients receiving GAHT, and those changes may be influenced by inflammation. However, these changes often return to baseline as TGNC patients’ bodies adjust to a new hormonal equilibrium.
Literatur
1.
2.
3.
•• Defreyne J, Elaut E, Kreukels B, Fisher AD, Castellini G, Staphorsius A, et al. Sexual desire changes in transgender individuals upon initiation of hormone treatment: results from the longitudinal european network for the investigation of gender incongruence. J Sex Med. 2020;17:812–25. This cross-sectional and prospective study assessed solitary, dyadic, and total sexual desire in trans men and women during the first three years of GAHT.
4.
Aranda G, Halperin I, Gomez-Gil E, Hanzu FA, Seguí N, Guillamon A, et al. Cardiovascular risk associated with gender affirming hormone therapy in transgender population. Front Endocrinol. 2021;12:718200.CrossRef
5.
Weinand JD, Safer JD. Hormone therapy in transgender adults is safe with provider supervision; a review of hormone therapy sequelae for transgender individuals. J Clin Transl Endocrinol. 2015;2:55–60.PubMedPubMedCentral
6.
Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher A, Toye K, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. J Sex Med. 2014;11:1999–2011.PubMedCrossRef
7.
White AA, Lin A, Bickendorf X, Cavve BS, Moore JK, Siafarikas A, et al. Potential immunological effects of gender-affirming hormone therapy in transgender people – an unexplored area of research. Ther Adv Endocrinol. 2022;13:204201882211396.CrossRef
8.
• Defreyne J, Vander Stichele C, Iwamoto SJ, T’Sjoen G. Gender-affirming hormonal therapy for transgender and gender-diverse people—a narrative review. Best Pract Res Clin Obstet Gynaecol. 2023;86:102296. This narrative review presents a comprehensive overview of changes associated with GAHT.
9.
Fisher AD, Castellini G, Ristori J, Casale H, Cassioli E, Sensi C, et al. Cross-sex hormone treatment and psychobiological changes in transsexual persons: two-year follow-up data. J Clin Endocrinol Metab. 2016;101:4260–9.PubMedCrossRef
10.
11.
Bungener Sara L, De Vries ALC, Popma A, Steensma TD. Sexual experiences of young transgender persons during and after gender-affirmative treatment. Pediatrics. 2020;146:e20191411.PubMedCrossRef
12.
• Gieles NC, Van De Grift TC, Elaut E, Heylens G, Becker-Hebly I, Nieder TO, et al. Pleasure please! Sexual pleasure and influencing factors in transgender persons: an ENIGI follow-up study. Int J Transgender Health. 2023;24:212–24. This is one of the few studies investigating sexual pleasure--not just sexual function or dysfunction--in TGNC populations.
13.
T’Sjoen G, Arcelus J, De Vries ALC, Fisher AD, Nieder TO, Özer M, et al. European Society for Sexual Medicine Position Statement “Assessment and Hormonal Management in Adolescent and Adult Trans People, with Attention for Sexual Function and Satisfaction.” J Sex Med. 2020;17:570–84.PubMedCrossRef
14.
15.
Holmberg M, Arver S, Dhejne C. Supporting sexuality and improving sexual function in transgender persons. Nat Rev Urol. 2019;16:121–39.PubMedCrossRef
16.
Kranz GS, Wadsak W, Kaufmann U, Savli M, Baldinger P, Gryglewski G, et al. High-dose testosterone treatment increases serotonin transporter binding in transgender people. Biol Psychiat. 2015;78:525–33.PubMedCrossRef
17.
Colizzi M, Costa R, Pace V, Todarello O. Hormonal treatment reduces psychobiological distress in gender identity disorder, independently of the attachment style. J Sex Med. 2013;10:3049–58.PubMedCrossRef
18.
Colizzi M, Costa R. The effect of cross-sex hormonal treatment on gender dysphoria individuals; mental health: a systematic review. NDT. 2016;12:1953–66.CrossRef
19.
• Zaliznyak M, Lauzon M, Stelmar J, Yuan N, Smith SM, Garcia MM. Effects of gender-affirming hormone therapy on orgasm function of transgender men and women: a long term follow up. Urology. 2023;174:86–91. This study compared orgasm function of trans men and women before and after the initiation of GAHT, comparing new function to cis populations.
20.
Stroumsa D, Crissman HP, Dalton VK, Kolenic G, Richardson CR. Insurance coverage and use of hormones among transgender respondents to a national survey. Ann Fam Med. 2020;18:528–34.PubMedPubMedCentralCrossRef
21.
• Ristori J, Cocchetti C, Castellini G, Pierdominici M, Cipriani A, Testi D, et al. Hormonal treatment effect on sexual distress in transgender persons: 2-year follow-up data. J Sex Med. 2020;17:142–51. This cross-sectional and prospective study assesses sexual distress (building upon studies that assess dysfunction but not associated distress) in trans men and women during the first year of GAHT.
22.
•• McQuillan MT, Kuhns LM, Miller AA, McDade T, Garofalo R. Gender minority stress, support, and inflammation in transgender and gender-nonconforming youth. Transgender Health. 2021;6:91–100. This study explores inflammatory changes associated with minority stress in TGNC youth and young adults.
23.
Khodamoradi K, Khosravizadeh Z, Parmar M, Kuchakulla M, Ramasamy R, Arora H. Exogenous testosterone replacement therapy versus raising endogenous testosterone levels: current and future prospects. F&S Reviews. 2021;2:32–42.CrossRef
24.
Nieschlag E, Mauss J, Coert A, Kićović P. Plasma androgen levels in men after oral administration of testosterone or testosterone undecanoate. Acta Endocrinol. 1975;79:366–74.
25.
Simon JA. Estrogen replacement therapy: effects on the endogenous androgen milieu. Fertil Steril. 2002;77:77–82.CrossRef
26.
27.
Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Women’s Health. 2012;21:161–9.CrossRef
28.
29.
Santen RJ, Pinkerton JV, Liu JH, Matsumoto AM, Lobo RA, Davis SR, et al. Workshop on normal reference ranges for estradiol in postmenopausal women, September 2019, Chicago, Illinois. Menopause. 2020;27:614–24.PubMedCrossRef
30.
Fait T. Menopause hormone therapy: latest developments and clinical practice. DIC. 2019;8:1–9.CrossRef
31.
Kopper N, Gudeman J, Thompson DJ. Transdermal hormone therapy in postmenopausal women: a review of metabolic effects and drug delivery technologies. Drug Des Devel Ther. 2008;2:193–202.
32.
• Schutte MH, Kleemann R, Nota NM, Wiepjes CM, Snabel JM, T’Sjoen G, et al. The effect of transdermal gender-affirming hormone therapy on markers of inflammation and hemostasis. Sánchez-Rodríguez MA, editor. PLoS One. 2022;17:e0261312. This exploratory study analyzed markers of inflammation and hemostasis in in trans men and women taking transdermal GAHT in order to better understand CVD risk.
33.
Toufexis D, Rivarola MA, Lara H, Viau V. Stress and the reproductive axis. J Neuroendocrinology. 2014;26:573–86.CrossRef
34.
Patacchioli FR, Simeoni S, Monnazzi P, Pace M, Capri O, Perrone G. Menopause, mild psychological stress and salivary cortisol: Influence of long-term hormone replacement therapy (HRT). Maturitas. 2006;55:150–5.PubMedCrossRef
35.
Viau V. Functional cross-talk between the hypothalamic-pituitary-gonadal and -adrenal axes. J Neuroendocrinology. 2002;14:506–13.CrossRef
36.
Janele D, Lang T, Capellino S, Cutolo M, Da Silva JAP, Straub RH. Effects of testosterone, 17β-estradiol, and downstream estrogens on cytokine secretion from human leukocytes in the presence and absence of cortisol. Ann N Y Acad Sci. 2006;1069:168–82.PubMedCrossRef
37.
Spratt DI, Longcope C, Cox PM, Bigos ST, Wilbur-Welling C. Differential changes in serum concentrations of androgens and estrogens (in relation with cortisol) in postmenopausal women with acute illness. J Clin Endocrinol Metab. 1993;76:1542–7.PubMed
38.
39.
Xue L, Tao L, Li X, Wang Y, Wang B, Zhang Y, et al. Plasma fibrinogen, d-dimer, and fibrin degradation product as biomarkers of rheumatoid arthritis. Sci Rep. 2021;11:16903.PubMedPubMedCentralCrossRef
40.
Thachil J, Favaloro EJ, Lippi G. D-dimers—“Normal” levels versus elevated levels due to a range of conditions, including “D-dimeritis”, inflammation, thromboembolism, disseminated intravascular coagulation, and COVID-19. Semin Thromb Hemost. 2022;48:672–9.PubMedCrossRef
41.
42.
43.
Levin RJ. The physiology of sexual arousal in the human female: a recreational and procreational synthesis. Arch Sex Behav. 2002;31:405–411
44.
Bouchard KN, Dawson SJ, Shelley AJ, Pukall CF. Concurrent measurement of genital lubrication and blood flow during sexual arousal. Biol Psychol. 2019;145:159–66.PubMedCrossRef
45.
Georgiadis JR, Kringelbach ML, Pfaus JG. Sex for fun: a synthesis of human and animal neurobiology. Nat Rev Urol. 2012;9:486–98.PubMedCrossRef
46.
Cheng JC, Secondary J, Burke WH, Fedoroff JP, Dwyer RG. Neuroimaging and sexual behavior: identification of regional and functional differences. Curr Psychiatry Rep. 2015;17:55.PubMedCrossRef
47.
Patel A, Zhu Y, Kuzhikandathil EV, Banks WA, Siegel A, Zalcman SS. Soluble interleukin-6 receptor induces motor stereotypies and co-localizes with Gp130 in regions linked to cortico-striato-thalamo-cortical circuits. Esteban FJ, editor. PLoS One. 2012;7:e41623.PubMedPubMedCentralCrossRef
48.
Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta (BBA)-Mol Cell Res. 2016;1863:1218–27.CrossRef
49.
Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol. 2012;33:315–27.PubMedPubMedCentralCrossRef
50.
Ye JH, Tao L, Zalcman SS. Interleukin-2 modulates N-methyl-d-aspartate receptors of native mesolimbic neurons. Brain Res. 2001;894:241–8.PubMedCrossRef
51.
Prossin AR, Zalcman SS, Heitzeg MM, Koch AE, Campbell PL, Phan KL, et al. Dynamic interactions between plasma IL-1 family cytokines and central endogenous opioid neurotransmitter function in humans. Neuropsychopharmacol. 2015;40:554–65.CrossRef
52.
Yohn SE, Arif Y, Haley A, Tripodi G, Baqi Y, Müller CE, et al. Effort-related motivational effects of the pro-inflammatory cytokine interleukin-6: pharmacological and neurochemical characterization. Psychopharmacology. 2016;233:3575–86.PubMedCrossRef
53.
Pollmacher T, Haack M, Schuld A, Reichenberg A, Yirmiya R. Low levels of circulating inflammatory cytokines—do they affect human brain functions? Brain Behav Immun. 2002;16:525–32.PubMedCrossRef
54.
Nappi RE, Polatti F. Continuing medical education: the use of estrogen therapy in women’s sexual functioning (CME). J Sex Med. 2009;6:603–16.PubMedCrossRef
55.
Klein C, Gorzalka BB. Continuing medical education: sexual functioning in transsexuals following hormone therapy and genital surgery: a review (CME). J Sex Med. 2009;6:2922–39.PubMedCrossRef
56.
Sartin-Tarm A, Lorenz T. Sexual trauma moderates hormonal mediators of women’s sexual function. Curr Sex Health Rep. 2022;14:207–21.CrossRef
57.
Cappelletti M, Wallen K. Increasing women’s sexual desire: the comparative effectiveness of estrogens and androgens. Horm Behav. 2016;78:178–93.PubMedCrossRef
58.
Wierckx K, Elaut E, Van Hoorde B, Heylens G, De Cuypere G, Monstrey S, et al. Sexual desire in trans persons: associations with sex reassignment treatment. J Sex Med. 2014;11:107–18.PubMedCrossRef
59.
McCabe MP, Sharlip ID, Atalla E, Balon R, Fisher AD, Laumann E, et al. Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med. 2016;13:135–43.PubMedCrossRef
60.
Basson R, Berman J, Burnett A, Derogatis L, Ferguson D, Fourcroy J, et al. Report of the international consensus development conference on female sexual dysfunction: definitions and classifications. J Urol. 2000;163:888–93.PubMedCrossRef
61.
Basson R. Review: testosterone therapy for reduced libido in women. Ther Adv Endocrinol. 2010;1:155–64.CrossRef
62.
Yassin AA, Saad F. Original research—endocrinology: improvement of sexual function in men with late-onset hypogonadism treated with testosterone only. J Sex Med. 2007;4:497–501.PubMedCrossRef
63.
Travison TG, Morley JE, Araujo AB, O’Donnell AB, McKinlay JB. The relationship between libido and testosterone levels in aging men. J Clin Endocrinol Metab. 2006;91:2509–13.PubMedCrossRef
64.
Corona G, Isidori AM, Buvat J, Aversa A, Rastrelli G, Hackett G, et al. Testosterone supplementation and sexual function: a meta-analysis study. J Sex Med. 2014;11:1577–92.PubMedCrossRef
65.
Goldstein I, Kim NN, Clayton AH, DeRogatis LR, Giraldi A, Parish SJ, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc. 2017;92:114–28.PubMedCrossRef
66.
Elraiyah T, Sonbol MB, Wang Z, Khairalseed T, Asi N, Undavalli C, et al. The benefits and harms of systemic testosterone therapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99:3543–50.PubMedPubMedCentralCrossRef
67.
Achilli C, Pundir J, Ramanathan P, Sabatini L, Hamoda H, Panay N. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril. 2017;107:475-482.e15.PubMedCrossRef
68.
Zheng J, Islam RM, Skiba MA, Bell RJ, Davis SR. Associations between androgens and sexual function in premenopausal women: a cross-sectional study. Lancet Diabetes Endocrinol. 2020;8:693–702.PubMedCrossRef
69.
Reed B, Bou Nemer L, Carr B. Has testosterone passed the test in premenopausal women with low libido? A systematic review. IJWH. 2016;8:599–607.CrossRef
70.
Gades NM, Jacobson DJ, McGree ME, St. Sauver JL, Lieber MM, Nehra A, et al. The associations between serum sex hormones, erectile function, and sex drive: the olmsted county study of urinary symptoms and health status among men. J Sex Med. 2008;5:2209–20.PubMedPubMedCentralCrossRef
71.
72.
Kao A, Binik YM, Amsel R, Funaro D, Leroux N, Khalifé S. Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment. J Sex Med. 2012;9:2066–76.PubMedCrossRef
73.
Santoro N, Worsley R, Miller KK, Parish SJ, Davis SR. Role of estrogens and estrogen-like compounds in female sexual function and dysfunction. J Sex Med. 2016;13:305–16.PubMedCrossRef
74.
Dow MGT, Hart DM, Forrest CA. Hormonal treatments of sexual unresponsiveness in postmenopausal women: a comparative study. BJOG. 1983;90:361–6.CrossRef
75.
Dennerstein L, Burrows G, Wood C, Hyman G. Hormones and sexuality: effect of estrogen and progestogen. Obstet Gynecol. 1980;56:316–7.PubMed
76.
Redmond GP. Hormones and sexual function. Int J Fertil Womens Med. 1999;44:193–7.PubMed
77.
78.
79.
80.
81.
Orr N, Wahl K, Joannou A, Hartmann D, Valle L, Yong P, et al. Deep dyspareunia: review of pathophysiology and proposed future research priorities. Sex Med Rev. 2020;8:3–17.PubMedCrossRef
82.
Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab. 2018;103:4146–54.PubMedCrossRef
83.
Abern L, Maguire K, Cook J, Carugno J. Prevalence of vulvar pain and dyspareunia in trans masculine individuals. LGBT Health. 2022;9:194–8.PubMedCrossRef
84.
Tordoff DM, Lunn MR, Chen B, Flentje A, Dastur Z, Lubensky ME, et al. Testosterone use and sexual function among transgender men and gender diverse people assigned female at birth. Am J Obstet Gynecol. 2023;229:669.e1-669.e17.PubMedCrossRef
85.
Barbonetti A, D’Andrea S, Francavilla S. Testosterone replacement therapy. Andrology. 2020;8:1551–66.PubMedCrossRef
86.
Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7:754–66.PubMedCrossRef
87.
Schmidt M, Naumann H, Weidler C, Schellenberg M, Anders S, Straub RH. Inflammation and sex hormone metabolism. Ann N Y Acad Sci. 2006;1069:236–46.PubMedCrossRef
88.
89.
Hoffmann JP, Liu JA, Seddu K, Klein SL. Sex hormone signaling and regulation of immune function. Immunity. 2023;56:2472–91.PubMedCrossRef
90.
Shepherd R, Cheung AS, Pang K, Saffery R, Novakovic B. Sexual dimorphism in innate immunity: the role of sex hormones and epigenetics. Front Immunol. 2021;11:604000.PubMedPubMedCentralCrossRef
91.
Shivers K-Y, Amador N, Abrams L, Hunter D, Jenab S, Quiñones-Jenab V. Estrogen alters baseline and inflammatory-induced cytokine levels independent from hypothalamic–pituitary–adrenal axis activity. Cytokine. 2015;72:121–9.PubMedPubMedCentralCrossRef
92.
Fedotcheva TA, Fedotcheva NI, Shimanovsky NL. Progesterone as an anti-inflammatory drug and immunomodulator: new aspects in hormonal regulation of the inflammation. Biomolecules. 2022;12:1299.PubMedPubMedCentralCrossRef
93.
Mohamad N-V, Wong SK, Wan Hasan WN, Jolly JJ, Nur-Farhana MF, Ima-Nirwana S, et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male. 2019;22:129–40.PubMedCrossRef
94.
Zhang X, Zhao H, Horney J, Johnson N, Saad F, Haider KS, et al. Testosterone deficiency, long-term testosterone therapy, and inflammation. J Cardiovasc Pharmacol Ther. 2021;26:638–47.PubMedCrossRef
95.
Grandys M, Majerczak J, Zapart-Bukowska J, Duda K, Kulpa JK, Zoladz JA. Lowered serum testosterone concentration is associated with enhanced inflammation and worsened lipid profile in men. Front Endocrinol. 2021;12:735638.CrossRef
96.
Tremellen K, McPhee N, Pearce K, Benson S, Schedlowski M, Engler H. Endotoxin-initiated inflammation reduces testosterone production in men of reproductive age. Am J Physiol-Endocrinol Metab. 2018;314:E206–13.PubMedCrossRef
97.
Yuxin L, Chen L, Xiaoxia L, Yue L, Junjie L, Youzhu L, et al. Research progress on the relationship between obesity-inflammation-aromatase axis and male infertility. Cheng K, editor. Oxidative Med Cell Long. 2021;2021:1–7.CrossRef
98.
Patel S. Disruption of aromatase homeostasis as the cause of a multiplicity of ailments: a comprehensive review. J Steroid Biochem Mol Biol. 2017;168:19–25.PubMedCrossRef
99.
Phumsatitpong C, Wagenmaker ER, Moenter SM. Neuroendocrine interactions of the stress and reproductive axes. Front Neuroendocrinol. 2021;63:100928.PubMedPubMedCentralCrossRef
100.
Yeager MP, Pioli PA, Guyre PM. Cortisol exerts bi-phasic regulation of inflammation in humans. Dose-Response. 2011;9:1.CrossRef
101.
Vitale C, Mendelsohn ME, Rosano GMC. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol. 2009;6:532–42.PubMedCrossRef
102.
Kannel WB. Menopause and risk of cardiovascular disease: the Framingham Study. Ann Intern Med. 1976;85:447.PubMedCrossRef
103.
Uddin SMI, Mirbolouk M, Dardari Z, Feldman DI, Cainzos-Achirica M, DeFilippis AP, et al. Erectile dysfunction as an independent predictor of future cardiovascular events: the multi-ethnic study of atherosclerosis. Circulation. 2018;138:540–2.PubMedCrossRef
104.
Clephane K, Wilson MC, Craig AN, Heiman JR, Lorenz TK. Inflammation predicts sexual arousability in healthy women. Compr Psychoneuroendocrinology. 2021;8:100086.CrossRef
105.
Clephane K, O’Loughlin JI, Bodnar TS, Wilson MC, Stariha JT, Craig AN, et al. Lack of evidence for a relationship between salivary crp and women’s sexual desire: an investigation across clinical and healthy samples. J Sex Med. 2022;19:745–60.PubMedPubMedCentralCrossRef
106.
Clephane K, Wilson MC, Heiman JR, Craig AN, Lorenz T. Sexual violence history predicts changes in vaginal immune parameters during sexual arousal. Brain Behav Immun. 2022;104:171–80.PubMedPubMedCentralCrossRef
107.
Yirmiya R, Avitsur R, Donchin O, Cohen E. Interleukin-1 inhibits sexual behavior in female but not in male rats. Brain Behav Immun. 1995;9:220–33.PubMedCrossRef
108.
Avitsur R, Pollak Y, Yirmiya R. Different receptor mechanisms mediate the effects of endotoxin and interleukin-1 on female sexual behavior. Brain Res. 1997;773:149–61.PubMedCrossRef
109.
Jokinen J, Chatzittofis A, Nordström P, Arver S. The role of neuroinflammation in the pathophysiology of hypersexual disorder. Psychoneuroendocrinology. 2016;71:55.CrossRef
110.
Lasselin J, Lekander M, Axelsson J, Karshikoff B. Sex differences in how inflammation affects behavior: what we can learn from experimental inflammatory models in humans. Front Neuroendocrinol. 2018;50:91–106.PubMedCrossRef
111.
112.
Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 1988;12:123–37.PubMedCrossRef
113.
Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007;21:153–60.PubMedCrossRef
114.
McKean KA, Nunney L. Bateman’s principle and immunity: phenotypically plastic reproductive strategies predict changes in immunological sex differences. Evolution. 2005;59:1510–7.PubMed
115.
Lorenz TK, Worthman CM, Vitzthum VJ. Links among inflammation, sexual activity and ovulation: evolutionary trade-offs and clinical implications. EMPH. 2015;2015:304–24.PubMedPubMedCentralCrossRef
116.
Vitzthum VJ. The ecology and evolutionary endocrinology of reproduction in the human female. Am J Phys Anthropol. 2009;140:95–136.PubMedCrossRef
117.
Cepon-Robins TJ, Blackwell AD, Gildner TE, Liebert MA, Urlacher SS, Madimenos FC, et al. Pathogen disgust sensitivity protects against infection in a high pathogen environment. Proc Natl Acad Sci USA. 2021;118:e2018552118.PubMedPubMedCentralCrossRef
118.
Milkowska K, Galbarczyk A, Jasienska G. Disgust sensitivity in relation to menstrual cycle phase in women with and without an infection. Am J Hum Biol. 2019;31:e23233.PubMedCrossRef
119.
Crosby CL, Buss DM, Meston CM. Sexual disgust: evolutionary perspectives and relationship to female sexual function. Curr Sex Health Rep. 2019;11:300–6.CrossRef
120.
121.
Pukall CF, Cahill CM. New Developments in the Pathophysiology of genital pain: role of central sensitization. Curr Sex Health Rep. 2014;6:11–9.CrossRef
122.
Fugl-Meyer KS, Bohm-Starke N, Damsted Petersen C, Fugl-Meyer A, Parish S, Giraldi A. Standard operating procedures for female genital sexual pain. J Sex Med. 2013;10:83–93.PubMedCrossRef
123.
Dong J-Y, Zhang Y-H, Qin L-Q. Erectile dysfunction and risk of cardiovascular disease. J Am Coll Cardiol. 2011;58:1378–85.PubMedCrossRef
124.
Masheb RM, Lozano-Blanco C, Kohorn EI, Minkin MJ, Kerns RD. Assessing sexual function and dyspareunia with the Female Sexual Function Index (FSFI) in women with vulvodynia. J Sex Marital Ther. 2004;30:315–24.PubMedCrossRef
125.
Avitsur R, Cohen E, Yirmiya R. Effects of interleukin-1 on sexual attractivity in a model of sickness behavior. Physiol Behav. 1997;63:25–30.PubMedCrossRef
126.
Klein SL, Nelson RJ. Activation of the immune–endocrine system with lipopolysaccharide reduces affiliative behaviors in voles. Behav Neurosci. 1999;113:1042–8.PubMedCrossRef
127.
Olsson MJ, Lundström JN, Kimball BA, Gordon AR, Karshikoff B, Hosseini N, et al. The scent of disease: human body odor contains an early chemosensory cue of sickness. Psychol Sci. 2014;25:817–23.PubMedCrossRef
128.
Shirasu M, Touhara K. The scent of disease: volatile organic compounds of the human body related to disease and disorder. J Biochem. 2011;150:257–66.PubMedCrossRef
129.
Regenbogen C, Axelsson J, Lasselin J, Porada DK, Sundelin T, Peter MG, et al. Behavioral and neural correlates to multisensory detection of sick humans. Proc Natl Acad Sci USA. 2017;114:6400–5.PubMedPubMedCentralCrossRef
130.
Baumeister RF. Gender differences in erotic plasticity: the female sex drive as socially flexible and responsive. Psychol Bull. 2000;126:347–74.PubMedCrossRef
131.
Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Vasiliadou C, Alexopoulos N, et al. Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J. 2006;27:2640–8.PubMedCrossRef
132.
Telfer MM, Tollit MA, Pace CC, Pang KC. Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents. Med J Aust. 2018;209:132–6.PubMedCrossRef
133.
Coleman E, Radix AE, Bouman WP, Brown GR, De Vries ALC, Deutsch MB, et al. Standards of care for the health of transgender and gender diverse people, Version 8. Int J Transgender Health. 2022;23:S1-259.CrossRef
134.
Tsatsanis C, Elenkov A, Leijonhufvud I, Vaporidi K, Tivesten Å, Giwercman A. Sex hormone-dependent and -independent regulation of serum BAFF and TNF in cohorts of transgender and cisgender men and women. Endocr Connect. 2023;12:e220456.PubMedPubMedCentralCrossRef
135.
Connelly PJ, Marie Freel E, Perry C, Ewan J, Touyz RM, Currie G, et al. Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults. Hypertension. 2019;74:1266–74.PubMedCrossRef
136.
Wilson R, Spiers A, Ewan J, Johnson P, Jenkins C, Carr S. Effects of high dose oestrogen therapy on circulating inflammatory markers. Maturitas. 2009;62:281–6.PubMedCrossRef
137.
Lake JE, Miao H, Bowman ER, Clark JL, Hyatt AN, Kettelhut A, et al. Gender-affirming hormone therapy decreases d-dimer but worsens insulin sensitivity in transgender women. HIV Med. 2023;24:1144–9.PubMedCrossRef
138.
Moreira Allgayer RMC, Borba GDS, Moraes RS, Ramos RB, Spritzer PM. The effect of gender-affirming hormone therapy on the risk of subclinical atherosclerosis in the transgender population: a systematic review. Endocr Pract. 2023;29:498–507.PubMedCrossRef
139.
Iannantuoni F, Salazar JD, De Marañon AM, Bañuls C, López-Domènech S, Rocha M, et al. Testosterone administration increases leukocyte-endothelium interactions and inflammation in transgender men. Fertil Steril. 2021;115:483–9.PubMedCrossRef
140.
Giltay EJ, Fonk JCM, Schalkwijk C, Gooren LJG. In vivo effects of sex steroids on lymphocyte responsiveness and immunoglobulin levels in humans. J Clin End Metabol. 2000;85(4):1648–1657.
141.
142.
Dubois LZ. Associations between transition-specific stress experience, nocturnal decline in ambulatory blood pressure, and C-reactive protein levels among transgender men. Am J Hum Biol. 2012;24:52–61.PubMedCrossRef
143.
Bartolucci C, Gómez-Gil E, Salamero M, Esteva I, Guillamón A, Zubiaurre L, et al. Sexual quality of life in gender-dysphoric adults before genital sex reassignment surgery. J Sex Med. 2015;12:180–8.PubMedCrossRef
144.
Manieri C, Castellano E, Crespi C, Di Bisceglie C, Dell’Aquila C, Gualerzi A, et al. Medical treatment of subjects with gender identity disorder: the experience in an Italian Public Health Center. Int J Transgenderism. 2014;15:53–65.CrossRef
145.
Wierckx K, Elaut E, Van Caenegem E, Van De Peer F, Dedecker D, Van Houdenhove E, et al. Sexual desire in female-to-male transsexual persons: exploration of the role of testosterone administration. Eur J Endocrinol. 2011;165:331–7.PubMedCrossRef
146.
Elaut E, De Cuypere G, De Sutter P, Gijs L, Van Trotsenburg M, Heylens G, et al. Hypoactive sexual desire in transsexual women: prevalence and association with testosterone levels. Eur J Endocrinol. 2008;158:393–9.PubMedCrossRef
147.
Bockting W, Benner A, Coleman E. Gay and bisexual identity development among female-to-male transsexuals in North America: emergence of a transgender sexuality. Arch Sex Behav. 2009;38:688–701.PubMedCrossRef
148.
Van Dijk D, Dekker MJHJ, Conemans EB, Wiepjes CM, De Goeij EGM, Overbeek KA, et al. Explorative prospective evaluation of short-term subjective effects of hormonal treatment in trans people—results from the European Network for the Investigation of Gender Incongruence. J Sex Med. 2019;16:1297–309.PubMedCrossRef
149.
Costantino A, Cerpolini S, Alvisi S, Morselli PG, Venturoli S, Meriggiola MC. A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery. J Sex Marital Ther. 2013;39:321–35.PubMedCrossRef
150.
Kerckhof ME, Kreukels BPC, Nieder TO, Becker-Hébly I, Van De Grift TC, Staphorsius AS, et al. Prevalence of sexual dysfunctions in transgender persons: results from the ENIGI Follow-Up Study. J Sex Med. 2019;16:2018–29.PubMedCrossRef
151.
Nobili A, Glazebrook C, Arcelus J. Quality of life of treatment-seeking transgender adults: a systematic review and meta-analysis. Rev Endocr Metab Disord. 2018;19:199–220.PubMedPubMedCentralCrossRef
152.
153.
Valentine SE, Shipherd JC. A systematic review of social stress and mental health among transgender and gender non-conforming people in the United States. Clin Psychol Rev. 2018;66:24–38.PubMedPubMedCentralCrossRef
154.
Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: a systematic review and meta-analysis. Brain Behav Immun. 2019;79:24–38.PubMedCrossRef
155.
Robinson GA, Peng J, Peckham H, Butler G, Pineda-Torra I, Ciurtin C, et al. Investigating sex differences in T regulatory cells from cisgender and transgender healthy individuals and patients with autoimmune inflammatory disease: a cross-sectional study. Lancet Rheumatol. 2022;4:e710–24.PubMedPubMedCentralCrossRef
156.
Rohleder N, Kudielka BM, Hellhammer DH, Wolf JM, Kirschbaum C. Age and sex steroid-related changes in glucocorticoid sensitivity of pro-inflammatory cytokine production after psychosocial stress. J Neuroimmunol. 2002;126:69–77.PubMedCrossRef
Metadaten
Titel
Inflammation as a Potential Mechanism Contributing to Sexual Functioning Following Initiation of Gender-Affirming Hormone Therapy
verfasst von
Molly K. Irvin
Dannielle Schutz
Tierney K. Lorenz
Publikationsdatum
02.04.2024
Verlag
Springer US
Erschienen in
Current Sexual Health Reports / Ausgabe 2/2024
Print ISSN: 1548-3584
Elektronische ISSN: 1548-3592
DOI
https://doi.org/10.1007/s11930-024-00385-2

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise